Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

27.83
+0.09000.32%
Post-market: 27.75-0.0798-0.29%19:34 EDT
Volume:1.17M
Turnover:32.71M
Market Cap:4.80B
PE:12.68
High:28.24
Open:27.98
Low:27.74
Close:27.74
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.80
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.67
PE(LYR):12.10

Loading ...

Acadia Pharmaceuticals - on Aug 24, Court Preliminarily Approves Settlement of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing

THOMSON REUTERS
·
5 hours ago

Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Sep 03

ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank

TIPRANKS
·
Aug 25

Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating

MT Newswires Live
·
Aug 25

U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials

Reuters
·
Aug 25

Acadia Pharmaceuticals Gets European Approval of Rett Syndrome Drug Daybu

Dow Jones
·
Aug 24

EU Approves Acadia’s DAYBU for Rett Syndrome Symptoms in Patients 5 and Older

Reuters
·
Aug 24

European Commission Approves Daybu® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

THOMSON REUTERS
·
Aug 24

Acadia Pharmaceuticals - Receives Ec Marketing Authorization for Daybu for Rett Syndrome

THOMSON REUTERS
·
Aug 24

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TIPRANKS
·
Aug 18

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)

Simply Wall St.
·
Aug 18

UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating

MT Newswires Live
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Aug 12

Acadia Pharmaceuticals Inc. : Needham Raises Target Price to $41 from $38

THOMSON REUTERS
·
Aug 12

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

MT Newswires Live
·
Aug 10

ACADIA Pharmaceuticals (ACAD) Gets a Buy from Citi

TIPRANKS
·
Aug 10

Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

Acadia Pharmaceuticals CFO Mark C. Schneyer Disposes of 25,141 Common Shares Worth $730,047.52

Reuters
·
Aug 08

ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus

Simply Wall St.
·
Aug 06